Table of Content

1. Introduction to LAG-3 Inhibitor
1.1 Overview
1.2 Historical Perspective


2. LAG-3 Targeted Approach in Cancer Therapy


3. LAG-3 as Therapeutic Target in Parkinson Disease
3.1 LAG-3 in PD Progression
3.2 LAG-3 as Potential Biomarker for PD


4. Role of LAG-3 in Viral Infections


5. LAG-3 as Potential Target in Autoimmune Diseases


6. LAG3 Inhibitor - Mechanism of Action


7. Therapeutic Approaches for Novel LAG-3 Targeted Therapy
7.1 Fusion Proteins
7.2 Monoclonal Antibodies
7.3 Bispecific Antibodies


8. Global LAG-3 Inhibitor Clinical Trials Overview
8.1 By Company
8.2 By Country
8.3 By Indication
8.4 By Patient Segment
8.5 By Phase



9. Global LAG-3 Inhibitor Clinical Trials Insight 2028
9.1 Research
9.2 Preclinical
9.3 Phase-I
9.4 Phase-I/II
9.5 Phase-II
9.6 Phase-II/III
9.7 Preregistration


10. Global LAG-3 Inhibitor Market
10.1 Current Market Scenario
10.2 Market Opportunity Assessment


11. Eftilagimod Alpha – Patent Insights
11.1 US
11.2 Europe
11.3 Japan
11.4 Rest of World


12. Relatlimab – FDA Orphan & Priority Review Designated LAG3 Inhibitor


13. Global LAG3 Inhibitor Market Dynamics
13.1 Market Drivers
13.2 Commercialization Challenges


14. Global LAG3 Inhibitor Market Future Outlook


15. Competitive Landscape
15.1 Avacta
15.2 Bristol Myers Squibb
15.3 F-Star Therapeutics
15.4 GlaxoSmithKline
15.5 Immutep
15.6 Innovent
15.7 Macrogenics
15.8 Merck
15.9 Nanobiotix
15.10 Novartis
15.11 Symphogen



List of Figures

Figure 1-1: LAG3/MHC class II Signaling Pathway

Figure 2-1: LAG-3 Signaling in Cancer Cell

Figure 3-1: Implication of LAG-3 in PD Progression
Figure 3-2: Biomarker Potential of LAG-3 in Parkinson Disease

Figure 4-1: LAG-3 on T Cells during HIV Infection

Figure 5-1: LAG-3 Associated Autoimmune Disorders

Figure 6-1: LAG3 Inhibitor – Mechanism of Action

Figure 7-1: Binding Efficacy of Bispecific Antibodies

Figure 8-1: Global – LAG 3 Inhibitor Clinical Trials By Company, 2022 till 2028
Figure 8-2: Global – LAG 3 Inhibitor Clinical Trials By Country, 2022 till 2028
Figure 8-3: Global – LAG 3 Inhibitor Clinical Trials By Indication, 2022 till 2028
Figure 8-4: Global – LAG 3 Inhibitors Clinical Trials By Patient Segment, 2022 till 2028
Figure 8-5: Global – Number of LAG 3 Inhibitors In Clinical Trials By Phase, 2022 till 2028

Figure 10-1: Global – Cancer Incidences & Deaths (Million), 2020
Figure 10-2: Global – Cancer Immunotherapy Market Size (US$ Billion), 2020 - 2028
Figure 10-3: Global – LAG3 Inhibitor Market Opportunity by 1% Cancer Immunotherapy Market (US$ Billion), 2022 - 2028
Figure 10-4: Global – LAG3 Inhibitor Market Opportunity by 2% Cancer Immunotherapy Market (US$ Billion), 2022 - 2028
Figure 10-5: Global – LAG3 Inhibitor Market Opportunity by 3% Cancer Immunotherapy Market (US$ Billion), 2022 - 2028

Figure 10-6: Global – LAG3 Inhibitor Market Opportunity by 4% Cancer Immunotherapy Market (US$ Billion), 2022 - 2028
Figure 10-7: Global – LAG3 Inhibitor Market Opportunity by 5% Cancer Immunotherapy Market (US$ Billion), 2022 - 2028
Figure 10-8: Global – LAG3 Inhibitor Market Opportunity by 6% Cancer Immunotherapy Market (US$ Billion), 2022 - 2028
Figure 10-9: Global – LAG3 Inhibitor Market Opportunity by 7% Cancer Immunotherapy Market (US$ Billion), 2022 - 2028
Figure 10-10: Global – LAG3 Inhibitor Market Opportunity by 8% Cancer Immunotherapy Market (US$ Billion), 2022 - 2028
Figure 10-11: Global – LAG3 Inhibitor Market Opportunity by 9% Cancer Immunotherapy Market (US$ Billion), 2022 - 2028
Figure 10-12: Global – LAG3 Inhibitor Market Opportunity by 10% Cancer Immunotherapy Market (US$ Billion), 2022 - 2028

Figure 11-1: US - Eftilagimod Alpha Patent Approval & Expiration Year
Figure 11-2: Europe - Eftilagimod Alpha Patent Approval & Expiration Year
Figure 11-3: Japan - Eftilagimod Alpha Patent Approval & Expiration Year
Figure 11-4: Australia - Eftilagimod Alpha Patent Approval & Expiration Year
Figure 11-5: China - Eftilagimod Alpha Patent Approval & Expiration Year

Figure 12-1: Relatlimab – FDA Orphan & Priority Review Designation Year
Figure 12-2: Relatlimab - RELATIVITY-047 Phase-III Trial Initiation & Completion Year

Figure 13-1: Global – Cancer Incidences & Deaths (Million), 2020 & 2025
Figure 13-2: Global - LAG3 Inhibitor Market Drivers
Figure 13-3: Stages of Drug Development